Acute coronary syndromes
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) aged 20~70 years old; (2) have the indications of cardiovascular and cerebrovascular interventional therapy; (3) have the indications of double anti-platelet therapy with aspirin and clopidogrel, of which the patients with percutaneous coronary intervention persist in taking medicine for 1 years, and the patients with cerebrovascular diseases adhere to take the drug for 6 months; (4) patients are fully informed of the whole process of clinical diagnosis and treatment and potential adverse events. The various conditions that may occur in the clinical diagnosis and treatment, which are not related to this research and sign the informed consent; (5) the patient's hospitalization time is not less than 5 days after postoperation; (6) The compliance of patients is higher, which can lead to the completion of this project and follow up.
Exclusion criteria
Exclusion criteria: (1) patients with aspirin or clopidogrel anaphylaxis or intolerance, as well as patients with aspirin resistance detected by thromboelastography (TEG); (2) patients with hematological diseases, hemorrhagic diseases or bleeding; (3) patients with severe liver and kidney dysfunction; (4) combined with tumors, severe immune system diseases, or other end-stage diseases; (5) patients with a history of apoplexy or visceral hemorrhagic disease in half a year; (6) patients with severe heart failure (NYHA IV) or severe anemia (hemoglobin 180mmHg or diastolic pressure > 120mmHg); (8) there is a taboo antiplatelet therapy or a recent surgical procedure; (9) women in pregnancy and lactation; (10) blood donation or as a volunteer of blood sampling in the last 3 months;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhibition of platelet aggregation;Concentration of clopidogrel acid;adverse events; | — |
Countries
China
Contacts
Yijishan Hospital of Wannan Medical College